SCHEMBL19783135

SCHEMBL19783135

COc1cc(C(O)C2CCOCC2)c2nc(N)sc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NSD1 Q96L73 2/20 0.34
NSD2 O96028 1/20 0.34
NSD3 Q9BZ95 1/20 0.34
PIK3CA P42336 3/20 0.33
HSD17B10 Q99714 2/20 0.33
ALDH1A1 P00352 2/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.31
USP9X Q93008 1/20 0.31
HPGDS O60760 2/20 0.31
CTSE P14091 1/20 0.31
BACE1 P56817 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189901 1.00 CYP3A4 (0.39) CYP3A4CYP1A2CYP2C19MAPTTDP1
SCHEMBL21396119 0.87 ALDH1A1 (0.36) NPC1RAB9AALDH1A1KMT2AUSP9X
SCHEMBL30189887 0.87 ALDH1A1 (0.36) NPC1RAB9AALDH1A1KMT2AUSP9X
SCHEMBL19782902 0.78 NPC1 (0.33) CYP3A4CYP1A2CYP2C19MAPTTDP1
SCHEMBL19783590 0.76 NPC1 (0.35) MAPTTDP1NPC1RAB9AALDH1A1
SCHEMBL19783149 0.75 NPC1 (0.39) MAPTNPC1RAB9AKMT2A
SCHEMBL19782709 0.75 F2RL3 (0.56)
SCHEMBL30187531 0.75 F2RL3 (0.56)
SCHEMBL21379356 0.73 CYP3A4 (0.41) CYP3A4CYP1A2CYP2C19MAPTTDP1
SCHEMBL21379367 0.71 CYP3A4 (0.44) CYP3A4CYP1A2CYP2C19MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYP3A4 15/4885CYP1A2 200/4885CYP2C19 64/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYP3A4 18/4885CYP1A2 176/4885CYP2C19 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.